Summary
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
History
Revance was founded in 2002 as a biochemical technology research and development company with the mission to develop advanced treatments and products in aesthetic and therapeutic indications. Since then, Revance has become a pioneer in the development of toxin, filler and aesthetic device therapies, with a focus on offering best-in-class treatments to aesthetically conscious consumers.
Mission
Our mission is to develop and market high-quality, innovative aesthetic and therapeutic products with the objective of improving and enhancing quality of life for patients worldwide.
Vision
Commitment to Customers: Our first promise is to the patients, and health care providers who use our products. Our customers want something significantly better, and we are committed to delivering.
Commitment to Employees: We will treat you like we want you to treat our best customer. We will develop your career. We will shape the culture where everyone wants to belong.
Commitment to Shareholders: We will strive to scale our business to provide superior returns to our investors.
Key Team
Mr. Aubrey Rankin (Consultant)
Ms. Taryn Conway (VP of Marketing)
Jessica Serra (Head of Investor Relations & ESG)
Ms. Azita Nejad (Sr. VP of Technical Operations)
Mr. Dwight Moxie (Sr. VP, Gen. Counsel & Corp. Sec.)
Ms. Jeanie D. Herbert (Sr. Director of Investor Relations & Corp. Communications)
Mr. Justin Ford (Sr. VP of HR & Head of People)
Recognition and Awards
Revance Therapeutics has been recognized for its innovation and commitment to being a leader in aesthetic medicine. In 2019, Revance was selected as a winner of SmartCEO’s 2019 Executive Management Award. In addition, the company was ranked #7 on Deloitte’s 2018 Technology Fast 500. It was also named to the 2017 Fierce 15 list of top 15 veteran-founded companies by FierceBiotech and was featured on the CNBC Disruptor 50 list in 2016.
References
United States 